How AI Is Being Used in Study Startup and Where It Adds Work

Introduction

Study startup is filled with information-heavy tasks. Teams review protocols, collect site documents, assess feasibility, track approvals, and coordinate with multiple stakeholders before a site can begin enrolling. That makes it an obvious area for AI in clinical trials.

The challenge is that adding AI does not automatically make these processes faster. AI can summarize documents, extract information, identify missing details, and support feasibility assessments. However, its outputs may still need human review, correction, and approval.

That distinction matters. A recent survey of more than 300 organizations found that only 10.7% had fully implemented AI or machine learning across the clinical development activities examined. Meanwhile, 30.3% were still piloting or beginning implementation.

So where is AI actually helping study startup, and where can it add work?

 Where AI Is Being Used in Study Startup

Study startup involves many processes that depend on finding, comparing, organizing, and moving information. That makes several activities suitable for AI assistance.

A recent analysis of study startup benchmarks illustrates why efficiency matters. In one 2026 benchmark analysis, the median time from receiving regulatory documents to submitting them was seven days, while the median time from site activation to the first screened patient was 20 days.

These timelines highlight how much coordination, documentation, and follow-up can influence study startup. AI cannot eliminate every delay, but it can reduce repetitive work such as document review, data extraction, and task coordination.

AI Document Review

Clinical research teams handle large volumes of protocols, regulatory materials, site information, and other study documents.

AI document review in clinical trials can help extract study requirements, identify missing information, and summarize key details.

For example, AI could extract specific requirements from a protocol and flag information that needs attention. Instead of searching through every document manually, a team member can start with an organized summary.

This can save time, but the output still requires human review. AI may miss an important qualification or misunderstand a requirement.

AI Feasibility Assessment

Feasibility is another area where AI can assist.

An AI feasibility assessment can process information about potential sites, including study experience, therapeutic-area capabilities, patient populations, enrollment history, and available resources.

For example, AI could organize data from dozens of potential sites and surface patterns that deserve attention.

However, the final decision requires context. A site may have strong historical enrollment but recently lost key staff, for example. AI can support the assessment, but it should not replace professional judgment.

AI Study Startup Workflows

AI can also support the broader AI study startup workflow by handling repetitive information and coordination tasks.

Potential applications include:

• Extracting information from submitted documents.
• Identifying missing fields.
• Generating summaries.
• Routing information to the right team.
• Flagging overdue tasks.
• Supporting milestone tracking.For example, AI could review startup documents and flag potential gaps. The coordinator can then verify the findings and resolve issues.

This is a more realistic model of AI adoption:

AI handles information-heavy work while people handle judgment-heavy work.

How AI Is Used in Clinical Trials Beyond Study Startup

The role of AI in clinical research extends beyond getting a study started.

Across the clinical trial lifecycle, AI can support areas such as:

• patient recruitment and matching.
• clinical data analysis.
• safety signal detection.
• monitoring activities.
• document processing.
• operational forecasting.
• trial planning.

The FDA has also recognized the need for appropriate controls around AI use in drug and biological product development. Its January 2025 draft guidance proposes a risk-based framework for assessing the credibility of AI models used to support regulatory decision-making.

The broader message is important: AI adoption needs to account for how the technology is being used and how its output will be evaluated.

Where AI Actually Adds Work

The biggest misconception about AI is that every automated step removes a human task. In clinical research, that is rarely the whole story. AI can reduce one type of work while creating another.

Human Review Still Matters

AI can review documents, extract information, or generate summaries in seconds. However, speed does not make the output automatically reliable.

A study startup team may still need to check whether the AI:

• captured the correct study requirements.
• interpreted the document accurately.
• missed an important detail.
• used the latest version of a document.
• preserved the original context.

This changes the task rather than eliminating it. Instead of manually finding every piece of information, the team reviews what the AI found and confirms that it is correct.

Validation Adds Another Step

AI-generated information may need to be checked against source documents before teams use it. The level of review should depend on how important the output is to the study.

Exceptions Need Human Judgment

Incomplete documents, conflicting information, or unusual requirements can fall outside what AI handles reliably. These cases still require a person to investigate and resolve them.

Integration Can Make or Break Efficiency

A separate AI tool can create more work if teams must move information between systems. AI adds the most value when it fits directly into the existing workflow.

The goal is not to automate more tasks. It is to reduce unnecessary work without adding new layers of review.

AI vs. Automation in Clinical Research

AI and automation are related, but they are not interchangeable.

What Good AI Implementation Looks Like

Before implementing AI into a clinical research workflow, teams should ask a few practical questions.

1. Does It Remove Work?

If users still have to copy information between systems, the technology may not be solving the underlying problem.

2. Where Is Human Review Needed?

Define which outputs require verification and who is responsible for that review.

3. Can the Output Be Traced?

Users should be able to understand where important information came from and verify it against the source.

4. How Are Exceptions Handled?

A useful system should make uncertain or incomplete cases visible instead of quietly pushing them through the workflow.

 5. Can Impact Be Measured?

Look beyond whether a team is “using AI.” Measure whether it reduces repetitive work, shortens workflow times, or improves visibility.

Where Syncora Fits Into AI-Enabled Clinical Research

Syncora focuses on the operational side of study startup, including site startup, study workflows, document management, automated alerts, and real-time tracking.

That creates an important foundation for AI-assisted workflows.

AI works better when the underlying information is organized and accessible. A centralized workflow can provide the structure needed to automate repetitive activities while keeping teams aware of tasks, documents, and milestones.

Syncora also highlights automation for feasibility questionnaires, document handling, compliance tracking, and site activation workflows.

The broader opportunity is not simply adding AI. It is creating a workflow where technology reduces administrative friction without removing necessary human oversight.

Conclusion

AI in clinical trials has clear potential to improve study startup. It can help teams process documents, organize feasibility information, identify gaps, and automate repetitive activities.

But AI does not make human involvement disappear.

Instead, it can shift the work from manual processing toward review, validation, exception handling, and decision-making. That shift is not necessarily a problem. The value comes when the new workload is smaller and more meaningful than the repetitive work it replaces.

For sponsors, CROs, and research sites, the better question is not, “Where can we add AI?”

It is: “Where can AI remove unnecessary work while keeping people in control of important decisions?”

That is the foundation for smarter clinical research workflows.